The present invention discloses oxazolidinone compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A and E, are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

##STR00001##

A compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 3-(4-isobutyl-2-methylphenyl)propyl represented by formula (I) ##STR00001##
is disclosed.

A compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 3-(4-isobutyl-2-methylphenyl)propyl represented by formula (I) ##STR00001##
is disclosed.

The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

Oxazolidione hydroxamic acid derivatives of the general formula (I):

##STR00001##

where R.sub.1 is hydrogen or hexanoyl and R.sub.2 is amino, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, cyclobutyl, pentyl, cyclopentyl, hexyl or heptyl, and pharmaceutically acceptable salts thereof, act as dual inhibitors of 5-lipoxygenase and mast cell degranulation. The oxazolidinone hydroxamic acid derivatives or pharmaceutically acceptable salts thereof can be used in the prevention and treatment of asthma and allergies, as well as inflammatory conditions.

Oxazolidione hydroxamic acid derivatives of the general formula (I):

##STR00001##

where R.sub.1 is hydrogen or hexanoyl and R.sub.2 is amino, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, cyclobutyl, pentyl, cyclopentyl, hexyl or heptyl, and pharmaceutically acceptable salts thereof, act as dual inhibitors of 5-lipoxygenase and mast cell degranulation. The oxazolidinone hydroxamic acid derivatives or pharmaceutically acceptable salts thereof can be used in the prevention and treatment of asthma and allergies, as well as inflammatory conditions.

Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.

Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.

A detergent, cleaning, fabric softener or cosmetic composition comprising a compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 3,7-dimethyl-1,6-nonyldien represented by formula (I) ##STR00001##
is disclosed.